Jobs Planet

Companies need help to discover candidates who are skilled enough to get hired. Companies put in a lot of effort to locatepersonnel who can meet their requirements. For a Job seeker, not having proper knowledge about an organization, its workculture, and its current job opening is a big challenge. Jobs Planet is a website that is a one-stop solution for Recruiters and Job Seekers. We reach a more comprehensive range ofaudiences for Recruiters who can connect with the right candidate and Job Seekers to get information about organizations andtheir current openings. For the Recruiters, recommendations are given based on the qualifications and skill set mentioned in thejob post. For Job Seekers, our website helps the users to easily navigate among the tabs to identify the openings as per theircompetency effortlessly. The website Jobs Planet is built from scratch to smoothen and shorten the hiring process, providing the ultimate search experiencefor Recruiters and Job Seekers and cost savings for the Recruiter. This application has a user-friendly interface with better searchresults due to the basic and advanced search options and various jobs available. Our website provides alerts and a trackingmechanism so that users (both the job seeker and Recruiter) know each step of progress in their application. The application is developed and is ready for release by the end of November 2022. Post the release, we aim to start with premiumservices on our website and develop a mobile application

Synthesis of Some Novel 1-​(Substituted Phenyl)​-​2-​(4-​(Trimethylsilyl)​-​1H-​1,​2,​3-​Triazol-​1-​yl) Ketones

A facile and highly efficient method for the regioselective one-​pot synthesis of a series of novel 1-​(substituted phenyl)​-​2-​(4-​(trimethylsilyl)​-​1H-​1,​2,​3-​triazol-​1-​yl)​ketones from 2-​bromo-​1-​(substituted phenyl)​ketones, sodium azide, and trimethylsilyl acetylene, through Cu (I) catalyzed 1,​3-​dipolar [3+2] cycloaddn. reaction is reported. The reaction proceeds smoothly in 40​% aq. acetone at room temp. without the use of any additive. Regioselectivity privileges the formation of the corresponding C-​4 silylated-​1,​2,​3-​triazoles in high yields in all instances. The methodol. offers an entry to new 1,​2,​3-​triazolyl-​4-​trimethylsilyl anionic synthon scaffolds

CURRENCY MISMATCHES IN EMERGING MARKET ECONOMIES: IS WINTER COMING?

We develop a currency mismatch index and examine the causes of currency mismatches in emerging market economies. This study is based on a unique dataset on 22 economies from 2008 to 2017. We also construct the original sin index using granular data on international debt securities. We find Latin American countries, followed by Central European countries, suffer from the original sin and currency mismatch problems. The panel regression estimates show that country size, trade openness, and the level of economic and financial development explain cross-country variations in currency mismatches. Our empirical results suggest that unstable monetary and fiscal policies are the primary causes of currency mismatches. The results indicate that a better institutional environment reduces currency mismatches. These findings call for monetary independence, stable fiscal policy, and macroprudential policy measures tominimize currency mismatches.We develop a currency mismatch index and examine the causes of currency mismatches in emerging market economies. This study is based on a unique dataset on 22 economies from 2008 to 2017. We also construct the original sin index using granular data on international debt securities. We find Latin American countries, followed by Central European countries, suffer from the original sin and currency mismatch problems. The panel regression estimates show that country size, trade openness, and the level of economic and financial development explain cross-country variations in currency mismatches. Our empirical results suggest that unstable monetary and fiscal policies are the primary causes of currency mismatches. The results indicate that a better institutional environment reduces currency mismatches. These findings call for monetary independence, stable fiscal policy, and macroprudential policy measures tominimize currency mismatches

HERBAL DRUG SWIETENIA MAHAGONI JACQ. -A REVIEW

ABSTRACT The dire need for such a review arises as the plant is included in the list of endangered species due to its high exploitation for timber utilization

Herbal immunomodulators as add on treatment in asymptomatic and mildly symptomatic COVID-19 confirmed cases: findings from a prospective single centre clinical trial

Background: The aim of the present study was to evaluate safety and efficacy of Sri Sri TattvaTM immunity products, a combination of single herb and poly herb formulations in COVID-19 patients by assessing their clinical features and immune markers. The products when administered orally for a period of 14 days in COVID-19 patients demonstrated significant improvement in clinical symptoms.Methods: Patients with fever, cough, sore throat started responding to the treatment from day 3 and most of the patients were clinically free of symptoms by day 7. Early recovery from signs and symptoms was observed in most of the patients. Sri Sri TattvaTM immunity products has also demonstrated an excellent clinical improvement and immune markers including tumor necrosis factor (TNF-alfa), interleukin (IL-6), interferon (IFN-beta), D-dimer, ferritin, lactate dehydrogenease (LDH) and C-reactive protein (CRP) in COVID-19 patients.Results: The final results of this study showed that Sri Sri TattvaTM immunity products reduced the time to clinical cure and number of days in achieving negative real time polymerase chain reaction (RT-PCR) by early viral clearance when given along with standard of care thus reduced the duration of hospitalization.Conclusions: In the present study, 82% of COVID-19 patients cleared the virus within 10-14 days of study period reducing the duration of hospitalization. None of the patients progressed to severe COVID-19 and succumbed to the disease. This clearly indicates that Sri Sri TattvaTM immunity products when administered orally along with standard of care has definitive role in the management of COVID-19 patients

Clinicopathological characteristics of colon cancers in a tertiary care centre

Background: Colon cancer is a leading cause of increase in cancer incidence and now becoming a major cause of cancer related mortality.Methods: We evaluated data of patients diagnosed with colon cancer and managed under Aarogyasri program between 2013 and 2019 at a tertiary care cancer hospital in Rajamahenderi, Andhra Pradesh, India. We collected data regarding demography, clinical presentation, subsite, histology, stage and treatment.Results: A total of 142 patients with colon cancer were managed. The mean age was 53.6 years with males accounting for 57%. Most common clinical presentation was abdominal pain followed by vomiting. Most common histology was well differentiated adenocarcinoma. Left sided colon tumors accounted for 47%. Most common stage at presentation was stage III.Conclusions: Our data of colon cancer was different from that described in the western countries. Young age presentation, higher mucinous and signet ring carcinomas and advanced stage presentation were reported in our study. Socioeconomic factors, inadequate health care access might account for some of these differences

RadioMe: Adaptive Radio with Music Intervention and Reminder System for People with Dementia in Their Own Home

The population of the world is continuously growing older, leading to more people with dementia who need support while living in their own home. Our RadioMe system was designed to adapt a live radio stream with reminders and music intervention for agitation mitigation for people with dementia living in their own home. In this demonstration we present our prototype, with features to record reminders and schedule them to be played during the live radio stream and a music intervention system when agitation is detected

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.

Funder: laura and john arnold foundationBACKGROUND: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). METHODS: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. RESULTS: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. CONCLUSIONS: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707